Lenvatinib can treat hepatocellular carcinoma, and thalidomide does not treat hepatocellular carcinoma. Lenvatinib belongs to the anti-angiogenic targeted drugs, which is mainly applied to unresectable hepatocellular carcinoma patients who have not received systemic systemic treatment before; while thalidomide is mainly used for type II leprosy, and can also be used for a variety of dermatologic diseases, such as discoid lupus erythematosus, subacute cutaneous lupus erythematosus, and Behçet’s syndrome. Lenvatinib may cause side effects such as high blood pressure, proteinuria, diarrhea, gastrointestinal perforation, hypokalemia, etc. Allergy to the ingredients of this medication, breastfeeding females, and pregnant females need to contraindicate this medication. Thalidomide may cause dryness of the mucous membranes of the mouth and nose, drowsiness and lethargy, constipation and nausea, rash and dizziness, and other side effects, children, pregnant women, lactating women, and people who are allergic to this drug are prohibited from using the drug. Lenvatinib and Thalidomide are both prescription drugs, the use of drugs must strictly follow the doctor’s instructions to avoid delays in the condition.